title: Cerebral perfusion response to successful treatment of depression with different serotoninergic agents.
abstract: In 19 patients with major depressive disorder, effective treatment with selective serotonin reuptake inhibitors (SSRIs) or amesergide (AMSG) was associated with increased cerebral perfusion in anterior cingulate cortex (SSRI and AMSG) and in medial prefrontal cortex (AMSG). Both selective serotonin reuptake inhibitors and AMSG exert antidepressant action through the serotonin (5-HT) system as reuptake inhibitors. Amesergide differs from SSRIs in that it is also a highly selective 5-HT antagonist, which may in part account for differences in cerebral blood flow response to treatment.
authors.affiliation: Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
authors.forename: Andrei
authors.initials: A
authors.lastname: Vlassenko
authors.forename: Yvette I
authors.initials: YI
authors.lastname: Sheline
authors.forename: Keith
authors.initials: K
authors.lastname: Fischer
authors.forename: Mark A
authors.initials: MA
authors.lastname: Mintun
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D001931:Brain Mapping; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects* / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods
chemical_list: D004873:Ergolines; D017367:Selective Serotonin Reuptake Inhibitors; C066736:amesergide